Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Deferred Revenue: 2012-2022

Historic Current Deferred Revenue for Ani Pharmaceuticals (ANIP) over the last 5 years, with Mar 2022 value amounting to $116,000.

  • Ani Pharmaceuticals' Current Deferred Revenue rose 16.00% to $116,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $116,000, marking a year-over-year increase of 16.00%. This contributed to the annual value of $100,000 for FY2021, which is negligibly% changed negligibly from last year.
  • Ani Pharmaceuticals' Current Deferred Revenue amounted to $116,000 in Q1 2022, which was up 16.00% from $100,000 recorded in Q4 2021.
  • Ani Pharmaceuticals' 5-year Current Deferred Revenue high stood at $735,000 for Q3 2018, and its period low was $100,000 during Q4 2020.
  • Over the past 3 years, Ani Pharmaceuticals' median Current Deferred Revenue value was $100,000 (recorded in 2021), while the average stood at $130,111.
  • In the last 5 years, Ani Pharmaceuticals' Current Deferred Revenue plummeted by 80.00% in 2020 and then grew by 16.00% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Current Deferred Revenue (Quarterly) stood at $711,000 in 2018, then declined by 29.68% to $500,000 in 2019, then plummeted by 80.00% to $100,000 in 2020, then remained steady at $100,000 in 2021, then grew by 16.00% to $116,000 in 2022.
  • Its Current Deferred Revenue stands at $116,000 for Q1 2022, versus $100,000 for Q4 2021 and $100,000 for Q3 2021.